For years, the economic story of independent pharmacy has been brutally simple: you get paid to dispense, and you are getting paid less every year.1-3 Margins shrink, fees multiply, and the path to survival narrows to filling more prescriptions faster for less money. Private equity-backed middlemen and consolidated buyers have turned that pressure into a business model, extracting value at every step while independents absorb the risk on the front lines.4-7
What almost no one tells independents is that they are already participating in a second, quieter economy—one built not on pills, but on data. Every refill gap, therapy change, prior authorization delay, and “I can’t afford that” at the counter is a datapoint. At scale, across thousands of pharmacies, those datapoints become the raw material for real-world evidence, payer analytics, manufacturer strategy, and investor theses.8-11 The data economy around pharmacy is thriving; the pharmacies themselves are not.
Automation, platforms, and “intelligent” tools are sold as the answer. Robotics will free up staff. Workflow engines will prioritize calls. Analytics dashboards will flag high-risk patients.12-14 Used well, these tools can absolutely reduce friction and create time for higher-value clinical work. But when the automation stack is owned and financed by the same forces that are squeezing reimbursement, independents should ask whether these tools are here to save their businesses—or to extract the last profitable bits while they struggle to breathe.4-6
A more radical, and more honest, framing is that independents sit on the ground floor of a potential independent pharmacy data economy—if they choose to claim it. That economy does not come from selling identifiable patient information; that is a non-starter. It comes from organizing, aggregating, and interpreting de-identified insights on medication behavior in ways that independents control and benefit from.15-17
In that world, automation is not the enemy; it is a lever. Intelligent systems help identify who needs outreach today, which clinical services move the needle on adherence, and where payer policies are causing predictable harm.12-14,18 Platform tools stop being 1-way extraction pipes and become bidirectional: independents feed in clean, structured data and get back insights that improve care and strengthen their negotiating position.
The pharmacist’s role evolves alongside the tools. The pharmacist of the future is not just a medication expert but a medication behavior analyst—someone who can look at refill patterns, switching trends, and intervention outcomes and say, “Here is what is really happening in this population, and here is what will actually change it.”19,20 That is a fundamentally different value proposition than, “We can fill this prescription cheaper,” and it is much harder for private equity spreadsheets to replace.4,21
What Does a Practical Path Out Look Like for Independents?
First, own your narrative and your numbers. Stop letting everyone else define your value purely in terms of cost per script. Track and understand your own adherence interventions, synchronization outcomes, and clinical touches, and bring those data into payer conversations and local contracting.1-3,22
Second, choose technology like an investor, not a captive customer. Prioritize vendors who are transparent about data rights, provide real analytical access back to you, and are willing to align their incentives with your success—not just your utilization.23-25
Third, collaborate horizontally, not just vertically. Independent pharmacies can pool de-identified data under governance structures they control, then partner upstream on their own terms. A network of independents with clean, governed data and documented clinical impact is a very different conversation than hundreds of isolated stores pleading for better reimbursement.1-3
About the Author
Noah A. Chapman is the founder and CEO of Veridex Lab, a health care data infrastructure company focused on unlocking the value of real-world pharmacy data. He has more than 27 years of experience in pharmacy and health care operations, including leadership roles at Walgreens, CVS Health, Benzer Pharmacy, Pierce Pharmacy Management, and Capsule, where he led national market expansion and technology-enabled pharmacy services. He began his career in 1999 on the overnight shift at Walgreens and has spent his career working at the intersection of independent pharmacy, health systems, and data-driven care.
Finally, build the pharmacist as a data-literate clinician. This does not mean every pharmacist needs a data science degree. It does mean building comfort with basic analytics, pattern recognition, and translating data into clinical and business decisions.19,20 The pharmacist who can say, “We prevented this many hospitalizations and improved adherence in this population” is no longer an easily commoditized dispenser and becomes central to any serious conversation about real-world evidence.
The current trajectory—shrinking margins, rising fees, and increasing dependence on platforms controlled by others—is not sustainable.1-3 But it is not inevitable either. Independents still sit where no algorithm, pharmacy benefit manager, or distant investor does: across from the patient, at the exact moment when care collides with reality.21
If they can turn that vantage point into a data asset they understand, control, and leverage, they have a shot at rewriting the rules of the game. The pharmacy data economy already exists. The only question left is whether independent pharmacies will keep powering it for everyone else—or finally start getting paid as full participants in it.
REFERENCES
Abraham PA, Kannarkat JT, Qato DM. Reforming markets to strengthen independent pharmacies. JAMA Health Forum. 2026;6(4):e250142. doi:10.1001/jamahealthforum.2025.0142
Shields Health Solutions advances health system-focused specialty pharmacy strategy as a private standalone company following acquisition by Sycamore Partners. News release. Shields Health Solutions. September 2, 2025. Accessed April 8, 2026. https://shieldshealthsolutions.com/shields-health-solutions-acquisition-by-sycamore-partners/
Roberts MH, Ferguson GT. Real-world evidence: bridging gaps in evidence to guide payer decisions. Pharmacoecon Open. 2021;5(1):3-11. doi:10.1007/s41669-020-00221-y
Masucci L, Lewis D, Zhao J, Carter C, Chan KW, Wong WL. The use of real-world evidence among healthcare payeres: a scoping review. Int J Technol Assess Health Care. 2025;41(1):e67. doi:10.1017/S0266462325100445
Framework for FDA’s real-world evidence program. FDA. December 2018. Accessed April 8, 2026. https://www.fda.gov/media/120060/download
Schroeder W. FDA real-world evidence: what does it really mean and how does it work? NAMSA. January 22, 2026. Accessed April 8, 2026. https://namsa.com/resources/blog/fda-real-world-evidence/
Radečić D. Data science in pharma – top 12 real-world examples. Appsilon. Updated April 2025. Accessed April 8, 2026. https://www.appsilon.com/post/data-science-in-pharma
Hernandez I, Tang S, Morales J, et al. Role of independent versus chain pharmacies in providing pharmacy access: a nationwide, individual-level geographic information systems analysis. Health Aff Sch. 2023;1(1):qxad003. doi:10.1093/haschl.qxad003
Laurent A. Pharmacy management systems: a guide to software & vendors. Intuition Labs. Updated February 24, 2026. Accessed April 8, 2026. https://intuitionlabs.ai/articles/pharmacy-management-systems-guide
